Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.42 |
| ▸ | CDK1 | P06493 | 3/20 | 0.42 |
| ▸ | PIM1 | P11309 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | GSK3A | P49840 | 3/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781802 | 0.85 | DYRK1A (0.48) | CDK5CDK2CDK5R1CCNT1CCNA2 | |
| SCHEMBL19781539 | 0.83 | CLK1 (0.47) | RIPK2DYRK1ACLK1KCNH2PIK3CA | |
| SCHEMBL19781167 | 0.81 | DYRK3 (0.51) | RIPK2CDK5CDK2CDK5R1CCNT1 | |
| SCHEMBL19781131 | 0.81 | CLK1 (0.41) | CDK5CDK2CDK5R1ABL1CCNT1 | |
| SCHEMBL19781806 | 0.79 | GRK5 (0.48) | ABL1DYRK1ACLK1KCNH2PIK3CA | |
| SCHEMBL19781810 | 0.78 | KCNH2 (0.43) | RIPK2DYRK1ACLK1KCNH2FDPS | |
| SCHEMBL24460223 | 0.77 | BCL2 (0.44) | DYRK1AMAP4K4CLK1KCNH2PIK3CA | |
| SCHEMBL19781168 | 0.77 | SCN5A (0.50) | RIPK2DYRK1ACLK1KCNH2PIK3CA | |
| SCHEMBL19781553 | 0.77 | SCN5A (0.50) | RIPK2DYRK1ACLK1KCNH2PIK3CA | |
| SCHEMBL19781776 | 0.77 | FYN (0.54) | RIPK2CLK1KCNH2PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | C3AR1, C9, C1R | RIPK2 2998/4885GSK3B 3181/4885CDK5 356/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | RIPK2 2353/4885GSK3B 4217/4885CDK5 1085/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | RIPK2 2353/4885GSK3B 4217/4885CDK5 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.